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Abstract 
Background: Immunogenicity of Streptokinase, as a thrombolytic drug, has limited its clinical use. Elimination 
of the amino acid residues that are responsible for immunogenicity while don’t affect the bioactivity of 
streptokinase is worthy. Recently, we modified the streptokinase through the elimination of 42 amino acids 
from its’ C-terminal and assessed its bioactivity in vitro. In this study, bioactivity of the mutated-streptokinase 
determined and compared with those of commercially available streptokinase (Heberkinase) in rabbits with 
induced blood clot. 
Materials and Methods: . Recombinant mutated streptokinase was purified and its lipopolysaccharide  
contained  remove and evaluated by LAL test. Thrombolytic activity of drug was evaluated by rabbit jugular 
vein as in vivo thrombosis model. The thrombolytic property of the drug was evaluated with determining of D-
dimer in plasma.  
Results:. The results showed in vivo bioactivity of both truncated and commercial streptokinase (p<0.05). 
This study showed an important influence of the 42 amino acids of C-terminal in bioactivity of the 
streptokinase. 
Conclusion: Clinical use of the r-streptokinase requires more modification to restore its’ activity in vivo. This 
product may be a promising choice for clinical use after confirmation of its stability and non-immunogenicity. 
Keywords: Thrombolysis; Recombinant streptokinase; Thrombolytic agent; Fibrinolytic activity; Jugular 
vein; Clot formation  
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Introduction 
The blood clot is formed through a complicated 
mechanism in which many proteins are involved. This 
phenomenon usually occurs after surgery, wound, 
myocardial infraction (MI), and so forth. After a clot 
formation, a healthy hemostatic system can remove 
blood clot from the blood circulation system. 
However, the removal of clot in some certain diseases 
such as pulmonary embolism, stroke, acute MI, or 
deep vein thrombosis in which the hemostatic system 




Streptokinase and tissue plasmin activator (TPA) are 
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among the most important thrombolytic agents used 
in clinics
2
. Streptokinase is normally used in clinical 
thrombosis therapy
3
. This enzyme has been the first 
choice for acute MI treatment for more than 40 years
4
. 
Streptokinase is a plasminogen-activator containing 
414 amino acid that is produced by several strains of 
β-hemolytic streptococci
5
. This thrombolytic agent 




It contains several structural domains (i.e., a-, h- and 
g-domains) with different functions
7
. The coiled 
region of the streptokinase ϒ-domain is necessary for 
plasminogen activation
8
. Binding the plasminogen to 
the lysine binding site of streptokinase causes 
conformational activation of plasminogen
9
. Although 
streptokinase is considered and applied as a promising 
thrombolytic agent, its immunogenicity has remained 
challenging
10
 so that with the administration of 
streptokinase, the body immune system produces 
antibodies against it. The titer of antibody raises 




Some studies have identified that the streptokinase 
has 5 antigenic regions containing 1-13, 14-127, 1-
253, 120-353, 353-414
12
. It has been also found that 
the deletion of 42 amino acid from the C-terminal 
region of wild streptokinase leads to the production of 
a truncated-streptokinase with decreased 
immunogenicity property
13
. In a previous study, we 
eliminated 42 amino acids from the C-terminal region 




the bioactivity of the r-streptokinase was evaluated in 
vitro
15
. The objective of the present study was to 
investigate the bioactivity property of this modified 
agent in vivo. For this purpose, a blood clot was 
induced in the jugular vein of rabbits. The rate of 
thrombolysis was then evaluated after the 
intravascular administration of the r-streptokinase. 
Methods 
All experimental methods were approved by ethical 
committee of Shahid Beheshti University of Medical 
Sciences (Permit Number: 3.9852) with the 
recommendations in the Guide for the Care and Use 
of Laboratory Animals.  
Cloning: In our previous study, the r-streptokinase 
(lacking 42 amino acid from C-terminal) was cloned 
into pGEMEX-1 expression vector with BamHӀ and 
SacӀ restriction enzymes
14
. The PCR product of r-
streptokinase was sub-cloned into pET32a by the 
same restriction enzymes and transformed in BL21 
(DE3) E.coli stain for protein expression. 
Expression and Purification of r-streptokinase: 
The transformed bacterial cells, Escherichia coli 
strain BL21 (DE3), were cultured in LB broth 
medium until reaching the mid-log phase. Thereupon, 
1mM isopropyl-1-thio-β-D galactopyranoside (IPTG), 
as an expression-inducing agent, was added to the 
medium and the cells were incubated for 5 hours at 
37ºC. After the incubation time, the cells were 
harvested, washed and the protein was purified using 
affinity chromatography with S.Tag resin. The 
samples were then dialyzed in PBS for 1 hour. The 
final concentration of the r-streptokinase in the 
samples has been increased by dry sucrose. 
SDS-PAGE and Western Blotting: The purified r-
streptokinase was characterized and detected by SDS-
polyacrylamide gel electrophoresis and western 
blotting. Briefly, the cell lysate was collected and 
mixed with protein lysis buffer/5 µl PMSF and 
centrifuged in 4000 rpm for 5 minutes. The 
supernatant was discarded and the pellet was mixed 
with 20 µL deionized water. After adding 20 µl 2-
Mercaptoethanol, the sample was heated in 85ºC for 5 
minutes. The samples were run in 10% SDS –
Polyacrylamid gel
16
 and observed after staining with 
1% (wt./vole) Coomassie Brilliant blue R-250. To 
detect the r-streptokinase with specific antibody, the 
gel was transferred to nitrocellulose sheet, blocked 
with Skim milk in PBS at 4 C ° for 24 hours and 
washed with PBS containing 0.05 % Tween-20. The 
samples were incubated and then detected by 
antibody. 
Bacterial Endotoxin Assay: The endpoint 
chromogenic limulus amebocyte lysate (LAL) is a 
qualitative test for the measurement of gram-negative 
bacterial endotoxin, which is called also 
lipopolysaccharide (LPS)
17
. This test is based on the 
capability of a serine protease enzyme in the digestion 
of LPS leading to clot formation. Briefly, the purified 
r-streptokinase was mixed with the LAL and 
incubated at 37°C (±1°C) for 10 minutes. A substrate 
solution was added to the LAL-sample (Cambrex 
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LAL) and incubated for 6 minutes at 37°C (±1°C). 
The samples were examined for clot formation. 
Removal of LPS: LPS has a strong antigenicity and 
the injection of this agent into the body stimulates 
immune system profoundly that ultimately can lead to 
allergic reactions. Therefore, the full removal of this 
agent is critical for the in vivo administration of the r-
streptokinase. One ml of the purified r-streptokinase 
was mixed with one ml Triton X-114 and centrifuged 
in 1000 rpm for five minutes. The last step was 
repeated three times. The supernatant was recollected 
and remixed with the LAL-sample to confirm the full 
removal of the LPS. 
In Vivo Study 
Rabbit Housing: The in vivo study was performed on 
six adult male New Zealand White rabbits weighing 
2.4±0.3 kg (mean±SD). The animals were purchased 
from Pasteur institute of Iran and acclimatized in an 
animal house under standard conditions for one week 
prior to use. All studies were performed under the 
approval of the laboratory of the Animal Care and 
Use Committee on Animal Investigations
18
.  
Surgery: Rabbit jugular vein was used as an in vivo 
thrombosis model to evaluate the fibrinolytic activity 
of recombinant streptokinase. For this purpose, the 
artificial thrombus in the jugular vein was induced as 
explained by Collen et al,
19
. The in vivo study 
performed in this study is illustrated in Figure 1. 
Briefly, the blood samples were taken from the 
marginal ears of rabbit for the measurement of D-
dimer before inducing thrombosis (Figure 1a). 
Animals were then generally anesthetized with 
ketamine HCl (35 mg/kg IM) (Alfamime; Alfasan, 
Woerden, Holland) and xylazine (5 mg/kg IM) 
(Rompun; Bayer, Leverkusen, Germany). After the 
general anesthesia, an external jugular vein was 
exposed and carefully dissected from the main 
bifurcation of the external jugular vein and the facial 
vein (Figure 1b). When bleeding was stopped, two 
clamps were placed on both sides of the vein 
proximally and distally to isolate a vein segment 
(Figure 1c). Then, the closed vein was emptied of all 
blood by suction via the catheter. Volumetric syringe 
was used for the measurement of the volume of the 
segment by the injection of saline. Approximately 100 
µl of human fibrinogen (10 mg fibrinogen mixed with 
500 µl PBS) aspirated in a 1.0-ml syringe was mixed 
with a volume of fresh rabbit blood. Then, 0.5 mg 
human thrombin (Sigma, 100 UN) was mixed with 
1ml PBS 1x, and 100 µL was injected into external 
jugular vein quickly (Figure 1d). It took 30 minutes 
that blood clot was formed and both vessel clamps 
were removed. At the end of the study, to follow the 
guidelines of animal welfare and prevent any 
sufferance, rabbits were euthanized with an overdose 
of intravenous sodium phenobarbital. The clot 
formation in the jugular vein was confirmed by 
Doppler sonography.  
Administration of Drug: After blood clot formation, 
the blood sample was collected through marginal ear 
vein in each group and coded as pre-drug 
administration. The r-streptokinase (500 µl estimated 
4000 U/kg, but not determined) was injected into the 
marginal ear vein (Figure 1e). The animals that 
received normal saline were considered as negative 
control group. The third group was injected with 
commercial streptokinase (Heberkinase) at the dose of 
4000 U/kg. After 1 hour (Figure 1f), the blood sample 
was obtained from each group (was coded as after 
drug administration) and transferred into the tube 
supplemented with sodium citrate, as an anticoagulant 
agent. The samples were centrifuged in 5000 rpm for 
5 minutes and the plasma was collected for the 
measurement of D-dimer level. 
Results 
The results obtained from PCR were analyzed and 
confirmed by 1% agaros gel electrophoresis as 
indicated in Figure 2, as lanes 1 and 2 indicates the 
bands of DNA ladder marker (ranging from 1-10kbp) 
and r-streptokinase plus universal primers (1116 bp), 
respectively (Figure 2).  
SDS-PAGE: The collected bacterial samples were 
lysed by lysis buffer and subjected to electrophoresis 
on 10% SDS-PAGE. The samples were stained by 
Coomassie Brilliant Blue R250 in order to detect the 
presence of the r-streptokinase. The stained SDS-
PAGE is shown in Figure 3, as lanes 1, 2 and 3 
indicate the lysate of BL21 containing r-streptokinase 
(KDa: 42 kDa for recombinant streptokinase) 5 hours 
after induction by IPTG, the lysate of BL21 without 
induction and the lysate of BL21 without plasmid, 
respectively (Figure 3).  
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Doppler Ultrasound: Blood flow velocity within the 
jugular vein was measured by Doppler ultrasound in 
order to confirm the induced thrombosis. The 
difference in frequency between transmitted and 
reflected ultrasound depends on the velocity of blood 
in the vessel. However, the intensity of the reflected 
Doppler signals depends on some other factors such 
as size of particles in the blood and their acoustic 
impedance
20
. As described above, the flow velocity 
was expected to increase after clot formation. The 
flow velocity in the jugular vein was recorded by 
Doppler ultrasound before and after thrombosis 
induction. As it can be observed in Figure 4, the flow 
velocity augmented approximately 25% after 1 hour 
of thrombosis induction (Figure 4).  
 
 
Figure 1. Summary of surgery and administration of truncated streptokinase in vivo. a) Collection of blood samples from marginal vein of 
rabbits’ ear. b) Jugular vein was exposed and separated from the facial and bifurcation vein. c) Two Clamps were placed on both sides of 
the vein (proximally and distally) to isolate a vein segment, then the closed vein was emptied of all blood by suction via the catheter. d) 
Injection of fibrinogen and thrombin for the formation of blood clot through jugular vein. e) Administration of rSTK and commercial STK 
through marginal ear vein of rabbit. f) The animal was maintained under anesthesia for 1 hour to allow the thrombolysis of drug. 
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D-Dimer Test: D-dimer measurement is a moderate 
to highly sensitive diagnostic tool for the presence of 
DVT (Venous Thromboembolism) or PE (Pulmonary 
Embolism) 
21
. For each experimental group, the level 
of D-dimer in plasma was measured before 
thrombosis induction and 1 hour after drug 
administration. For this purpose, two different 
antithrombotic agents were evaluated for their effects 
on the generation of thrombus. Separate groups of 
animals were used for each drug treatment and 
control. The control group received normal saline, r-
streptokinase at the dosage 4000 IU/Kg and 
Heberkinase (Heb) at the same dosage, respectively. 
The blood samples were taken before clot formation 
and one hour after thrombosis induction. Figure 5 
shows the significant difference before and after clot 
formation in each group. The level of D-dimer after 
the administration of the r-streptokinase and Heb was 
found to be significantly more than that in the control 
group. On the other hand, Heb group indicated an 
increased level of D-dimer in comparison with the r-
streptokinase experimental group (Figure 5).  
Discussion 
Streptokinase as a bacterial enzyme, displays partial 
immunogenicity in the human body. Therefore, after 
the administration of streptokinase, the human body 
immune system is stimulated leading to the 
production of antibody (Ab) against streptokinase. 
The high titer of anti-streptokinase in the body may 
lead to both severe immune reactions during the 
streptokinase therapy and neutralization of 
streptokinase activity
17
. Although other thrombolytic 
agents such as UK and TPA are available
22
, but they 
 
 
Figure 2. 1 percentage agaros gel electrophoresis. Lane 1: DNA 




Figure 3. 10 percentage SDS-PAGE. Lane 1: Lysate of BL21 
contains rSTK 5 hours after induction. Lane 2: Lysate of BL21 
without induction. Lane 3: Lysate of BL21 without plasmid. 
 
 
Figure 4. Doppler ultrasound results. A) Flow velocity before thrombosis induction 18.5 cm/s. B) Flow velocity after thrombosis induction 25 
cm/s. C) Comparison between the flow velocities before and after clot formation. 
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are more expensive than streptokinase. Many efforts 
were made to overcome the immunogenicity of 
streptokinase. The detection and elimination of 
antigenic residues form streptokinase were considered 
as an efficient strategy in order to minimize its 
immunogenicity. One of the concerns arisen from 
such a strategy is that the deletion of some regions in 
streptokinase may affect its bioactivity. The 
determination of a region responsible for the 
immunogenicity of streptokinase is worthy. In 1995, 
Parhami-Seren et al.
23
 found three major antigenic 
regions in streptokinase through mapping the anti-
streptokinase antibody from the human sera, 
containing regions 1-253 and 120-352 (containing 
distinct, non-overlapping epitopes). Parhami-Seren et 
al.
23
 reported that two other epitopes in streptokinase 
constructed by amino acids 1-13 and 353-414 were 
not antigenic in all humans. In our previously 
published work, a region in the C-terminal of the 
streptokinase containing 42 amino acids was 
eliminated. The activity of the truncated streptokinase 
was then determined in vitro. According to our 
results, the elimination of 42 aa from the C-terminal 
of native streptokinase did not affect the activity of 
enzyme in vitro
14
. Our experiment showed that 
Iranian consumer streptokinase serum does not 
respond to mutant streptokinase in comparison to 
Heberkinase by ELISA method
25
. The purpose of the 
present study was to investigate the bioactivity of the 
same truncated streptokinase in vivo. For this 
purpose, a blood clot was induced in the jugular vein 
of New Zealand white rabbits. The r-streptokinase 
was administered intravascular and compared with the 
animals that received Heberkinase (a commercial 
Streptokinase) and normal saline as positive and 
negative controls, respectively. The thrombolysis 
property of drugs was quantified through the 
determination of D-dimer level in rabbit blood 
plasma.  
Many studies have been conducted to develop a 
strategy for the induction of thrombus in animal 
models
24
. For instance, Clozel et al,
25
 induced blood 
clot formation in rabbits’ jugular veins through 
thrombin and radioactive fibrinogens. Then, the level 
of degraded radioactive fibrinogen, representing the 
rate of thrombosis, was measured by using a gamma 
counter. In this study, the thrombus induced in the 
jugular vein of rabbit using fibrinogen and thrombin. 
The rate of thrombolysis was measured one hour after 
drug administration. The determination of 
thrombolysis in vivo is challenging due to limitations 
in the direct visualization of plaque and thrombus. 
Johnstone et al,
26
 used MRI to determine the exact 
location of thrombus formation in the rabbit model. In 
this study, the exact location of thrombus and the 
relationship between the thickness of the aortic 
stenosis and thrombus formation were defined by 
Doppler sonography.   
According to our results, streptokinase infusion 
increased the levels of D-dimers. Results showed  that 
the recombinant streptokinase displayed a detectable 
fibrinolytic activity when compared with before drug 
administration and negative control samples. In line 
with these observations, the infusion of 4000 IU of r-
streptokinase provoked the extensive systemic 
activation of  the fibrinolytic system. According to the 
D-dimer results, r-streptokinase significantly 
increased the level of D-dimer in rabbits’ plasma in 
comparison with negative control. Furthermore, the 
level of D-dimer in Heberkinase group had a 
significant increase in comparison with r-
streptokinase. This decrease in the bioactivity of the r-
streptokinase indicates the potential of the 42 amino 
acids of C-terminal in its bioactivity. It is important to 
 
 
Figure 5. D-dimer level in three experimental groups (Control: 
injected with normal saline, Heb: injected with Heberkinase 
injection, rSTK: injected with sterptokinase.  
* Significant difference (p<0.05). 
† Insignificant difference (p>0.05). 
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note that the synthesized r-streptokinase requires 
further  modifications to restore its full activity invivo 
and make it an efficient thrombolytic agent for 
clinical use. Since it was reported that the C-terminal 
of streptokinase is critical for its immunogenicity, the 
synthesized enzyme may be a promising choice for 
clinical use after the optimization of its full 
bioactivity. 
Conclusion 
Efficacy of C-terminal truncated-streptokinase in the 
elimination of blood clot was evaluated in rabbits. 
Our data indicated that the r-streptokinase had 
bioactivity invivo, but less than that in commercial 
streptokinase (Heberkinase). 
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